208 related articles for article (PubMed ID: 34456107)
1. Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity.
Maulik S; Arunsingh M; Arun B; Prasath S; Mallick I
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e52-e60. PubMed ID: 34456107
[TBL] [Abstract][Full Text] [Related]
2. Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.
Mallick I; Das A; Arunsingh M
Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):260-264. PubMed ID: 30718087
[TBL] [Abstract][Full Text] [Related]
3. Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.
Glicksman RM; Loblaw A; Morton G; Szumacher E; Chung HT; Vesprini D; Chu W; Liu SK; Choo R; Deabreu A; Mamedov A; Zhang L; Cheung P
Radiother Oncol; 2021 Oct; 163():21-31. PubMed ID: 34324914
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer.
Faria S; Ruo R; Perna M; Cury F; Duclos M; Sarshoghi A; Souhami L
Pract Radiat Oncol; 2020; 10(6):e514-e520. PubMed ID: 32738465
[TBL] [Abstract][Full Text] [Related]
5. Multi-Institutional Clinical Outcomes of Biopsy Gleason Grade Group 5 Prostate Cancers Treated With Contemporary High-Dose Radiation and Long-Term Androgen Deprivation Therapy.
Chilukuri S; Mallick I; Agrawal A; Maitre P; Arunsingh M; James FV; Kataria T; Narang K; Gurram BC; Anand AK; Utreja N; Dutta D; Pavamani S; Mitra S; Mallik S; Mahale N; Chandra M; Chinnachamy AN; Shahid T; Raghunathan MS; Kannan V; Mohanty SK; Basu T; Hotwani C; Panigrahi G; Murthy V
Clin Oncol (R Coll Radiol); 2023 Jul; 35(7):454-462. PubMed ID: 37061457
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
10. Moderately hypofractionated salvage radiotherapy in patients with biochemical recurrence of prostate cancer after prostatectomy: long-term results and comparative analysis of two schedules.
Matrone F; Donofrio A; Fanetti G; Revelant A; Polesel J; Chiovati P; Bortolus R
Neoplasma; 2022 Dec; 69(6):1425-1436. PubMed ID: 36305692
[TBL] [Abstract][Full Text] [Related]
11. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes.
Faria SL; Neto OB; Cury F; Shenouda G; Russel R; Souhami L
Can J Urol; 2016 Apr; 23(2):8209-14. PubMed ID: 27085825
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209
[TBL] [Abstract][Full Text] [Related]
13. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy.
Faria S; Ruo R; Cury F; Duclos M; Souhami L
Pract Radiat Oncol; 2017; 7(4):264-269. PubMed ID: 28222995
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z
Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
[TBL] [Abstract][Full Text] [Related]
17. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
18. Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer.
Tomita N; Soga N; Ogura Y; Furusawa J; Tanaka H; Koide Y; Tachibana H; Kodira T
Asia Pac J Clin Oncol; 2019 Feb; 15(1):18-25. PubMed ID: 30411504
[TBL] [Abstract][Full Text] [Related]
19. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
